A Phase 1 interventional study of RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B and Placebo in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 1 site in Japan. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-25.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 36th largest by enrollment, is one of 6 that started in 2019, is one of 5 in phase 1, and was the 12th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 6 started in 2019.
This study's enrollment of 40 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 doses of GSK Biologicals' RSV candidate vaccine adjuvanted with AS01B for the prevention of lower respiratory tract diseases caused by RSV in ethnic Japanese adults 60-80 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
Biological: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Drug: Placebo
Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).
Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1
Number of Subjects With Solicited Local AEs After Second Dose of Vaccination
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored with a diameter larger than (\>) 20 millimeters (mm).
Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61
Number of Subjects With Solicited General AEs After First Dose of Vaccination
Assessed solicited general AEs solicited were: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.
Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination administered at Day 1
Number of Subjects With Solicited General AEs After Second Dose of Vaccination
Assessed solicited general AEs solicited are: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms including (nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.
Time frame: During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination administered at Day 61
Number of Subjects With Unsolicited AEs After Any Vaccination
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination (across doses)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose When Compared to Day 1
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.
Time frame: At 7 days after the first vaccine dose (i.e. at Day 8 versus Day 1)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose When Compared to Day 61
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.
Time frame: At 7 days after the second vaccine dose (i.e at Day 68 versus Day 61)
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first vaccination
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second vaccination
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
Time frame: From Day 1 up to 30 days after the second vaccination (Day 91)
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology
Time frame: From Day 1 up to 30 days after the second vaccination (Day 91)
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV- Serotype A
Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). The cut-off of the assay is 18 ED60.
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples are based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL). The assay cut-off is 25 ELU/mL.
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Number of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14)
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Number of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Number of Subjects With Respiratory Tract Infection (RTI) Episodes Reported During RTI Surveillance
The number of RTI cases is provided by group. Reported categories are "RSV+ RTI" (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab collected at assessment visit) and "RSV- RTI" (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab collected at assessment visit).
Time frame: During the RSV seasons from Day 1 to Month 14
| Milestone | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Erythema | 1 | 0 |
| Pain | 17 | 1 |
| Swelling | 2 | 0 |
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored with a diameter larger than (\>) 20 millimeters (mm).
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Erythema | 0 | 0 |
| Pain | 17 | 4 |
| Swelling | 0 | 0 |
Assessed solicited general AEs solicited were: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Arthralgia | 1 | 0 |
| Fatigue | 9 | 2 |
| Fever | 0 | 0 |
| Gastrointestinal symptoms | 1 | 1 |
| Headache | 2 | 2 |
| Myalgia | 6 | 0 |
| Shivering | 1 | 0 |
Assessed solicited general AEs solicited are: arthralgia; fatigue; fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); gastrointestinal symptoms including (nausea, vomiting, diarrhea and/or abdominal pain); headache; myalgia and shivering.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Arthralgia | 5 | 0 |
| Fatigue | 9 | 1 |
| Fever | 4 | 0 |
| Gastrointestinal symptoms | 0 | 1 |
| Headache | 5 | 1 |
| Myalgia | 5 | 1 |
| Shivering | 4 | 0 |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Number of Subjects With Unsolicited AEs After Any Vaccination | 7 | 6 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| ALT-Above-Above | 1 | 0 |
| ALT-Within-Within | 19 | 20 |
| AST-Within-Above | 0 | 1 |
| AST-Within-Within | 20 | 19 |
| Basophils-Within-Within | 20 | 20 |
| Creatinine-Within-Below | 1 | 0 |
| Creatinine-Within-Within | 19 | 20 |
| Eosinophils-Below-Below | 3 | 1 |
| Eosinophils-Below-Within | 2 | 1 |
| Eosinophils-Within-Below | 2 | 1 |
| Eosinophils-Within-Within | 13 | 17 |
| Erythrocytes-Below-Below | 0 | 1 |
| Erythrocytes-Within-Below | 2 | 2 |
| Erythrocytes-Within-Within | 18 | 17 |
| Hemoglobin-Below-Below | 0 | 1 |
| Hemoglobin-Within-Below | 0 | 1 |
| Hemoglobin-Within-Within | 20 | 18 |
| Lymphocytes-Within-Within | 20 | 20 |
| Monocytes-Below-Below | 2 | 0 |
| Monocytes-Below-Within | 1 | 1 |
| Monocytes-Within-Below | 1 | 0 |
| Monocytes-Within-Within | 16 | 19 |
| Neutrophils-Below-Below | 1 | 0 |
| Neutrophils-Within-Within | 19 | 20 |
| Platelets-Within-Within | 20 | 20 |
| Urea Nitrogen-Above-Within | 1 | 0 |
| Urea Nitrogen-Within-Within | 19 | 20 |
| Uric Acid-Above-Above | 1 | 0 |
| Uric Acid-Above-Within | 2 | 0 |
| Uric Acid-Within-Above | 1 | 1 |
| Uric Acid-Within-Below | 1 | 0 |
| Uric Acid-Within-Within | 15 | 19 |
| White Blood Cells-Below-Below | 1 | 0 |
| White Blood Cells-Below-Within | 0 | 2 |
| White Blood Cells-Within-Below | 1 | 0 |
| White Blood Cells-Within-Within | 18 | 18 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as below, within or above the normal ranges.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| ALT-Within-Within | 20 | 20 |
| AST-Within-Above | 0 | 1 |
| AST-Within-Within | 20 | 19 |
| Basophils-Within-Within | 20 | 20 |
| Creatinine-Below-Below | 0 | 1 |
| Creatinine-Within-Above | 0 | 1 |
| Creatinine-Within-Below | 1 | 0 |
| Creatinine-Within-Within | 19 | 18 |
| Eosinophils-Below-Within | 1 | 0 |
| Eosinophils-Within-Above | 1 | 0 |
| Eosinophils-Within-Within | 18 | 20 |
| Erythrocytes-Below-Below | 0 | 3 |
| Erythrocytes-Below-Within | 1 | 0 |
| Erythrocytes-Within-Below | 1 | 1 |
| Erythrocytes-Within-Within | 18 | 16 |
| Hemoglobin-Below-Within | 1 | 0 |
| Hemoglobin-Within-Below | 0 | 2 |
| Hemoglobin-Within-Within | 19 | 18 |
| Lymphocytes-Within-Within | 20 | 20 |
| Monocytes-Below-Below | 2 | 0 |
| Monocytes-Within-Below | 2 | 0 |
| Monocytes-Within-Within | 16 | 20 |
| Neutrophils-Below-Below | 1 | 1 |
| Neutrophils-Within-Below | 0 | 1 |
| Neutrophils-Within-Within | 19 | 18 |
| Platelets-Within-Within | 20 | 20 |
| Urea Nitrogen-Within-Within | 20 | 20 |
| Uric Acid-Above-Above | 0 | 1 |
| Uric Acid-Below-Below | 1 | 0 |
| Uric Acid-Within-Above | 1 | 1 |
| Uric Acid-Within-Below | 1 | 0 |
| Uric Acid-Within-Within | 17 | 18 |
| White Blood Cells-Below-Below | 1 | 0 |
| White Blood Cells-Below-Within | 2 | 1 |
| White Blood Cells-Within-Below | 0 | 1 |
| White Blood Cells-Within-Within | 17 | 18 |
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Any adverse event | 0 | 0 |
| General adverse event | 0 | 0 |
| Local adverse event | 0 | 0 |
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Any adverse event | 2 | 0 |
| General adverse event | 1 | 0 |
| Local adverse event | 1 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 | 1 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination | 0 | 0 |
Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). The cut-off of the assay is 18 ED60.
| Titers | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Day 1 | 727.3 (445.6 to 1187.3) | 656 (464.7 to 926.2) |
| Day 31 | 5315 (3452.8 to 8181.5) | 582.3 (372.1 to 911.2) |
| Day 61 | 4382.8 (2828.1 to 6792.1) | 646.1 (442.6 to 943.1) |
| Day 91 | 4605.2 (3031.2 to 6996.4) | 529.9 (352.4 to 796.9) |
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples are based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL). The assay cut-off is 25 ELU/mL.
| ELU/mL | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Day 1 | 6676.7 (4490 to 9928.2) | 7090.2 (5123.8 to 9811.4) |
| Day 31 | 85282.4 (66071.9 to 110078.4) | 7242.6 (5534.1 to 9478.6) |
| Day 61 | 54076.9 (40417.7 to 72352.2) | 5625.9 (4322.5 to 7322.3) |
| Day 91 | 61110.7 (45959 to 81257.6) | 5515.7 (4240.2 to 7174.8) |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any SAEs, up the End of Follow-up Study Period (Month 14) | 0 | 1 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Number of Subjects Reporting pIMDs up to the End of Follow-up Study Period (Month 14) | 0 | 0 |
The number of RTI cases is provided by group. Reported categories are "RSV+ RTI" (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab collected at assessment visit) and "RSV- RTI" (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab collected at assessment visit).
| Participants | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| RSV + RTI | 0 | 0 |
| RSV - RTI | 1 | 1 |
Collected over Solicited AEs were collected during the 7-day follow-up period after each vaccination. Unsolicited AEs were collected during the 30-day follow-up period after any vaccination. SAEs were collected during the whole study period, from Day 1 till Month 14.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV_PreF3_AS01B Group | 0/20 (0%) | 0/20 (0%) | 19/20 (95%) |
| Placebo Group | 0/20 (0%) | 1/20 (5%) | 10/20 (50%) |
| Event | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 0/20 | 1/20 |
| Ulna fractureInjury, poisoning and procedural complications | 0/20 | 1/20 |
| Event | RSV_PreF3_AS01B Group | Placebo Group |
|---|---|---|
| Injection site painGeneral disorders | 18/20 | 4/20 |
| FatigueGeneral disorders | 13/20 | 2/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/20 | 1/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/20 | 0/20 |
| HeadacheNervous system disorders | 7/20 | 3/20 |
| ChillsGeneral disorders | 6/20 | 0/20 |
| PyrexiaGeneral disorders | 5/20 | 0/20 |
| Injection site swellingGeneral disorders | 2/20 | 0/20 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/20 | 1/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/20 | 2/20 |
| Age, Continuous(Years) | RSV_PreF3_AS01B Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 65.2 ± 5.0 | 67.2 ± 4.2 | 66.2 ± 4.6 |
| Sex: Female, Male(Participants) | RSV_PreF3_AS01B Group | Placebo Group | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 10 | 10 | 20 |
| Race/Ethnicity, Customized(Participants) | RSV_PreF3_AS01B Group | Placebo Group | Total |
|---|---|---|---|
| Asian | 20 | 20 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2019 to primary completion in Jan 2020, 3 months.
Results were first posted in Feb 2022, 2 years 1 month after primary completion.
Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.
Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →